Vector Models and Indexing for Recombinant Protein Clinical

Data Characteristics

Recombinant protein clinical trial pre-screening data originates from global clinical trial registries (e.g., ClinicalTrials.gov, WHO ICTRP), biopharmaceutical company public reports, academic papers, patent literature, and specialized databases (e.g., UniProt, PDB). Update frequencies vary. Clinical trial registries may update weekly, while academic papers and patent literature are released irregularly. Document structures are diverse. Clinical trial data often includes structured fields like NCT ID, Study Title, Intervention, and Eligibility Criteria. Papers and patents primarily consist of unstructured text. Common fields and units include Dosage (mg/kg, IU), Duration (Weeks, Months), Efficacy Endpoints (e.g., percentages, numerical values), and various biomarker metrics.

Constraints from Data Characteristics on Vector Models and Indexing

The heterogeneity of recombinant protein data sources requires multimodal data processing and standardization before vectorization. For instance, structured fields must combine with unstructured text to build context. Inconsistent update frequencies necessitate incremental update capabilities for vector indexes, avoiding frequent full rebuilds. Diverse document structures demand flexible text segmentation strategies. These strategies must maintain the complete semantics of clinical trial records while extracting key information from lengthy papers. The specificity of fields and units, especially biomarker and dosage information, requires careful semantic consideration during vectorization. Simple word embeddings may lose the meaning of numerical data, potentially requiring customized feature engineering or pre-trained models.

Configuration Guidelines

Configuration Item	Suggested Value	Rationale
`Chunk size` (Segment Length)	`800–1200 characters` (characters)	Balances the completeness of clinical trial records with the information density of lengthy documents, preventing truncation of critical information.
`Recall count` (Recall Count)	`Top 10–20 entries` (top 10–20 items)	Ensures coverage for initial retrieval, providing sufficient candidates for subsequent re-ranking, and avoiding omission of highly relevant documents.
`Similarity threshold` (Similarity Threshold)	Calibrate based on actual measurements	Balances recall and precision according to actual pre-screening needs and data distribution, avoiding interference from irrelevant results.
`Rerank result count` (Re-ranking Return Count)	`Top 5 entries` (top 5 items)	Focuses on core results of user interest, reduces the burden of manual filtering, and improves pre-screening efficiency.
`UPLOAD_FILE_MAX_SIZE`	`500 MB`	Accommodates large clinical trial reports or documents with multiple attachments, ensuring successful file uploads.
`PARSE_FILE_TIMEOUT_SECONDS`	`600 seconds` (seconds)	Handles time-consuming parsing of complex PDFs or long texts, preventing file processing failures due to timeouts.

Common Pitfalls

The total number of vector data is less than the original data. This often results from file parsing failures or overly strict segmentation filtering strategies, leading to some documents not being successfully vectorized and indexed.
Index creation succeeds, but the page does not display. This may relate to communication failures between the backend indexing service and the frontend display layer, or an anomaly during index construction. Data may be indexed, but its status is not correctly updated.
Local vector retrieval is normal, but vector scores are inconsistent after deployment. This often occurs due to differences in dependency library versions in the deployment environment, or inconsistent model loading paths and runtime configurations, leading to deviations in vectorization model behavior.

Verification Steps

Check the number of documents in the vector library against the original data volume via the management interface. Sample and review the vectorization status of some documents.
Use representative recombinant protein clinical trial queries to observe the distribution of relevance scores in the recall results. This determines if the model can differentiate between different drugs and indications.
Perform multiple rounds of queries for specific recombinant proteins. Cross-reference whether the retrieval results include expected key clinical trial numbers (e.g., NCT ID) and relevant literature.
Test end-to-end retrieval response times in different network environments. Ensure preliminary results are obtained within 8 seconds (seconds), meeting the efficiency requirements of the actual pre-screening process.

***

Note: The values provided are common starting points. Measure against your own samples for optimal performance.

Question material comes from public community discussions. Configuration values are common starting points and should be measured against your own samples. Verified on 2026-09-21.